Abstract
Considerable research is aimed at determining the mechanisms by which hormone-refractory prostate cancer develops. In an effort to assist in the understanding of recurrent prostate cancer and the cellular processes that mediate this disease, a mathematical model is presented that describes both the pretreatment growth and the posttherapy relapse of human prostate cancer xenografts. Our goal is to evaluate the interplay between the multiple mechanisms that have been postulated as causes of androgen-independent relapse. Simulations of the model show that molecular events that render the androgen receptor irrelevant to disease progression, such as upregulation of BCL2, can result in relapse after androgen deprivation therapy. However, decreased apoptosis of androgen-independent cells alone overestimates the effects of hormone therapy when compared to experimental data. When decreased apoptosis is combined with continual androgen receptor activation, the posttherapy growth dynamics are in excellent correlation with experimental observations of the growth of LuCaP xenografts. Furthermore, the mathematical model predicts that upregulation of the androgen receptor, together with its increased activation, is alone sufficient to result in the androgen-independent growth of LNCaP xenografts. Recent experimental studies that suggest that the posttherapy increase in and continual activation of the androgen receptor are common and crucial features of recurrent prostate cancer provide validation of the model predictions. This approach provides a framework for using mathematical techniques to study novel therapeutic strategies aimed at controlling this disease.
MeSH Terms
Androgens/metabolism
Animals
Cell Line, Tumor
Cell Proliferation
Drug Resistance, Neoplasm/physiology
Humans
Male
Models, Theoretical
Neoplasm Recurrence, Local/pathology
Prostatic Neoplasms/pathology
Receptors, Androgen/metabolism
Transplantation, Heterologous
Chemicals
Androgens
Receptors, Androgen
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Jackson Trachette L
Department of Mathematics, 525 E. University, University of Michigan, Ann Arbor, MI 48109-1109, USA.
[email protected]
References (22)
22 references, click to expand
-
Hormone refractory prostate cancer.
Urology. 1999 Dec;54(6A Suppl):1-7
PMID: 10606277
-
Endocrine treatment in prostate cancer.
Semin Surg Oncol. 2000 Jan-Feb;18(1):52-74
PMID: 10617897
-
A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy.
Math Biosci. 2000 Mar;164(1):17-38
PMID: 10704636
-
Cancer statistics, 2000.
CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33
PMID: 10735013
-
Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer.
J Urol. 2000 Dec;164(6):1992-5
PMID: 11061898
-
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.
Cancer Res. 2001 Jun 1;61(11):4315-9
PMID: 11389051
-
Androgen receptor regulation of G1 cyclin and cyclin-dependent kinase function in the CWR22 human prostate cancer xenograft.
J Androl. 2001 Jul-Aug;22(4):537-48
PMID: 11451350
-
Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model.
Prostate. 2002 Mar 1;50(4):222-35
PMID: 11870800
-
Prostate cancer update.
Curr Opin Oncol. 2002 May;14(3):286-91
PMID: 11981273
-
Long-term effects of androgen deprivation therapy in prostate cancer patients.
Clin Endocrinol (Oxf). 2002 Jun;56(6):779-86
PMID: 12072048
-
Vascular tumor growth and treatment: consequences of polyclonality, competition and dynamic vascular support.
J Math Biol. 2002 Mar;44(3):201-26
PMID: 12148489
-
Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?
J Clin Endocrinol Metab. 2003 Jul;88(7):2972-82
PMID: 12843129
-
Prostate cancer.
N Engl J Med. 2003 Jul 24;349(4):366-81
PMID: 12878745
-
Molecular determinants of resistance to antiandrogen therapy.
Nat Med. 2004 Jan;10(1):33-9
PMID: 14702632
-
Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer.
J Biol Chem. 2004 Feb 20;279(8):7119-30
PMID: 14662770
-
On the growth and stability of cell cultures and solid tumors.
J Theor Biol. 1976 Jan;56(1):229-42
PMID: 1263527
-
Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration.
Int J Cancer. 1996 Jan 3;65(1):85-9
PMID: 8543402
-
A mathematical model of glioma growth: the effect of extent of surgical resection.
Cell Prolif. 1996 Jun;29(6):269-88
PMID: 8809120
-
The interaction of growth rates and diffusion coefficients in a three-dimensional mathematical model of gliomas.
J Neuropathol Exp Neurol. 1997 Jun;56(6):704-13
PMID: 9184661
-
Implication of cell kinetic changes during the progression of human prostatic cancer.
Clin Cancer Res. 1995 May;1(5):473-80
PMID: 9816006
-
Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.
Clin Cancer Res. 1996 Jun;2(6):1039-48
PMID: 9816265
-
Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration.
Int J Cancer. 1996 Sep 17;67(6):785-90
PMID: 8824549